Stevens-johnson syndrome and toxic epidermal necrolysis: Improving the support to victims

Drug Safety

Volumn 36, Issue 2, 2013, Pages 145-146

  Roujeau, Jean Claude ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; BASIC RESEARCH; CLINICAL RESEARCH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUSTRY; HEREDITY; HUMAN; IMMUNE RESPONSE; LETTER; MORTALITY; MUCOSA; PATIENT CARE; PRIORITY JOURNAL; RARE DISEASE; RISK ASSESSMENT; RISK FACTOR; SKIN; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

DRUG TOXICITY; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; INTERNET; PHARMACEUTICAL PREPARATIONS; STEVENS-JOHNSON SYNDROME;

EID: 84876589825     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-012-0008-4     Document Type: Letter

References (6)

1. Bounoua M, Valeyrie-Allanore L, Sekula P, et al. Evaluation prospective des séquelles de syndrome de Stevens-Johnson et de nécrolyse épidermique toxique dans une cohorte européenne de 339 malades. Ann Dermatol Venereol. 2007;134:7S12.
2. Butt TF, Cox AR, Oyebode JR, et al. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf. 2012;35(12):1159-70.
3. An example to us all. Prescrire Int. 2012;21:200.
4. Stevens-Johnson Syndrome Foundation [online]. Available from http://sjsupport.org/. Accessed 19 Nov 2012.
5. Valeyrie-Allanore L, Ingen-Housz-Oro S, Colin A, et al. Pain management in Stevens-Johnson syndrome, toxic epidermal necrolysis and other blistering diseases [in French]. Ann Dermatol Venereol. 2011;138:694-7.
6. Gaultier F, Rochefort J, Landru MM, et al. Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. Arch Dermatol. 2009;145:1332-3.